Aspirin Reduces Liver Fat in Clinical Trial of the Most Common Cause of Chronic Liver Disease
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Contact Information
Charles River Plaza
165 Cambridge Street, 9th Floor
Boston,
MA
02114
Phone: 617-726-6609
Fax: 617-724-5996
Hours: Monday–Friday, 8:00 am–5:00 pm
Services also available at:
Mass General North Shore Center for Outpatient Care
102-104 Endicott Street
Danvers, MA 01923
The prevalence of celiac disease in the U.S. has quadrupled over the past 50 years. The Celiac Disease Program at Mass General brings together an expert team of providers who work with patients with celiac disease to co-create health.
This multi-disciplinary care team is tailored to each patient’s unique condition. Our providers include:
We offer the full range of endoscopic diagnostic procedures critical for obtaining a tissue diagnosis and differentiating celiac disease from other disorders such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), microscopic colitis (lymphocytic and collagenous), eosinophilic and autoimmune enteritis, and irritable bowel syndrome (IBS).
Patient education and support are important components of our mission. We are committed to helping patients understand their disease, assess their treatment options, participate in their treatment decisions and feel in control of their disease. Our physicians are experienced in fine-tuning medical therapies and helping patients obtain relief from persistent, difficult-to-manage symptoms.
To help educate the community about how our diet, lifestyle and environment can affect GI health, our doctors participate in community events throughout the year.
The Celiac Disease Program at Mass General is a comprehensive program dedicated to the diagnosis and treatment of patients with celiac disease and all gluten-mediated disorders. The gastroenterology department at Massachusetts General Hospital is consistently ranked among the nation's top programs, with Magnet award-winning nurses providing patients with compassionate, timely care. Magnet designation represents the highest honor available for nursing excellence and is achieved by fewer than 7% of hospitals in the United States. Our multidisciplinary team of providers has been recognized both nationally and internationally for groundbreaking research and outstanding patient care.
We believe that each patient can significantly improve our knowledge of celiac disease and contribute toward understanding the factors that influence the development of this disease and factors that determine response to treatments. All of the physicians involved in the Celiac Disease Program actively participate in research programs aimed at understanding the underlying cause of celiac disease, with the goal of developing more effective treatment approaches.
Dr. Ramnik Xavier directs a research program that focuses on understanding the genetic basis of celiac disease based on genome-wide association studies. Dr. Xavier's research group actively collaborates with the lab of Dr. Cisca Wijmenga, a world leader in the genetics of celiac disease. In addition, Dr. Xavier works closely with Dr. Bana Jabri, a renowned immunologist who is working with Dr. Xavier to develop systems biology approaches to understanding the fundamental mechanisms underlying celiac disease.
Results warrant additional studies into the health benefits of aspirin for patients with metabolic dysfunction–associated steatotic liver disease.
Andrew Chan, MD, MPH is co-leading the global team known as PROSPECT, which received a grant of up to $25m over five years, to study early-onset colorectal cancer from Cancer Grand Challenges after an international competition.
Researchers have identified numerous genetic clusters that may help explain why people with type 2 diabetes have different clinical presentations.
We reached out to investigators at Massachusetts General Hospital and asked them to give us one science-backed action people can take to improve their heart health.
In a nationally representative of US adults with self-reported chronic liver disease (CLD), approximately 308,000 (6%) identified delaying medical care due to transportation barriers.
Michael Dougan, MD, PhD, is a senior author of a new study in Clinical Gastroenterology and Hepatology, Tofacitinib Is Effective in Treating Refractory Immune Checkpoint Inhibitor Hepatitis.